Stockscreener 앱 받기
0.65
3.25%
-0.0218
시간 외 거래:
.65
전일 마감가:
$0.6718
열려 있는:
$0.66
하루 거래량:
72,459
Relative Volume:
0.27
시가총액:
$30.45M
수익:
$10.85M
순이익/손실:
$-51.31M
주가수익비율:
-0.882
EPS:
-0.737
순현금흐름:
$-40.15M
1주 성능:
-4.91%
1개월 성능:
-7.16%
6개월 성능:
-58.86%
1년 성능:
-76.70%
1일 변동 폭
$0.65
$0.68
1주일 범위
$0.65
$0.7163
52주 변동 폭
$0.63
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.65 | 32.30M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Maxim Group | Buy |
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
NSPR|InspireMD Inc|Price:0.694|Chg%:+0.010 - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Cash Flow - TradingKey
NSPR|InspireMD Inc|Price:0.690|Chg%:+0.006 - TradingKey
InspireMD Inc. Revenue Breakdown – NASDAQ:NSPR - TradingView
InspireMD Inc. (NSPR) Q1 2026 Earnings: EPS Surpasses Estimates Despite Limited Revenue DisclosureGuidance Downgrade Alert - dars.gov.et
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD, Inc. Receives Notice of Delisting from NASDAQ – Form 8-K Filing July 2026 - Minichart
InspireMD Receives Nasdaq Minimum Bid Price Warning - Moomoo
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Receives Nasdaq Notice on Bid Price Compliance - TipRanks
InspireMD Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk - Stock Titan
InspireMD gets Nasdaq notice for failing $1 minimum bid price rule - Bitget
InspireMD director Raymond W. Cohen to resign from board effective July 1, 2026 - TradingView
Board member Raymond Cohen to leave InspireMD (NSPR) effective July 1, 2026 - Stock Titan
InspireMD (NSPR) Slips 4.5% on Selling Pressure, Tests Key Support LevelPut Spread Alert - dars.gov.et
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBIT forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
NSPR Q1 2026 Earnings: EPS Beat Surprises as Revenue Remains UndisclosedEPS Consistency Score - dars.gov.et
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key SupportMarket Leader Picks - dars.gov.et
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD (NSPR) Edges Higher but Faces Test at $0.77 ResistanceRating Change - dars.gov.et
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
InspireMD Inc. 주식 (NSPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | Chief Commercial Officer |
May 19 '26 |
Sale |
1.01 |
22,778 |
23,006 |
1,053,882 |
| Gleason Shane Thomas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.59 |
2,941 |
4,676 |
1,076,660 |
| Stuka Paul | Director |
May 13 '26 |
Buy |
1.16 |
10,000 |
11,575 |
642,871 |
| Stuka Paul | Director |
May 14 '26 |
Buy |
1.15 |
5,000 |
5,750 |
647,871 |
| Slosman Marvin | CEO and President |
May 12 '26 |
Buy |
1.20 |
21,000 |
25,200 |
3,556,658 |
| Stuka Paul | Director |
May 08 '26 |
Buy |
1.16 |
65,626 |
76,126 |
622,871 |
| Stuka Paul | Director |
May 11 '26 |
Buy |
1.19 |
10,000 |
11,900 |
632,871 |
| Ward Scott R. | Director |
May 07 '26 |
Buy |
1.15 |
73,255 |
84,243 |
237,096 |
| Ward Scott R. | Director |
May 06 '26 |
Buy |
1.15 |
15,995 |
18,394 |
163,841 |
| Stuka Paul | Director |
May 07 '26 |
Buy |
1.15 |
6,378 |
7,335 |
531,599 |
1.04%
11.95%
자본화:
|
볼륨(24시간):